Kelsey Perfect, PA
Physician Assistant · Portland, ORNPI 1528515475
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 255 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 255 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$855
- Novartis$611
- Lilly USA, LLC$589
- Xeris Pharmaceuticals, Inc.$472
- Dexcom, Inc.$449
- Novo Nordisk$384
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,228100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 44 | $855 |
| Novartis | 26 | $611 |
| Lilly USA, LLC | 28 | $589 |
| Xeris Pharmaceuticals, Inc. | 24 | $472 |
| Dexcom, Inc. | 21 | $449 |
| Novo Nordisk | 20 | $384 |
| AstraZeneca(2 entities) | 11 | $216 |
| Sanofi-aventis U.S. LLC | 9 | $207 |
| Boehringer Ingelheim | 8 | $185 |
| Medtronic | 8 | $159 |
| Corcept Therapeutics | 7 | $156 |
| Amryt Pharma Holdings Ltd | 4 | $98 |
| Bayer | 5 | $96 |
| Tandem Diabetes Care, Inc. | 4 | $81 |
| AbbVie | 5 | $73 |
| Radius Health, Inc. | 3 | $68 |
| Nevro Corp. | 3 | $62 |
| Merck | 4 | $56 |
| Pfizer | 2 | $54 |
| Ascensia Diabetes Care US Inc. | 2 | $51 |
| Ultragenyx Pharmaceutical Inc. | 3 | $48 |
| Madrigal Pharmaceuticals | 1 | $45 |
| GRT US Holding, Inc. | 2 | $39 |
| Mannkind Corporation | 2 | $32 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Antares Pharma, Inc. | 1 | $23 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Zealand Pharma US, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Insulet Corporation | 1 | $11 |
| Cequr Corporation | 1 | $11 |
How this compares
$5,240 in reported general payments places this provider in the 95th percentile of 1,756 physician assistant providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $172,889 |
| TymlosAbaloparatide | 36 | $111,325 |
| TrulicityDulaglutide | 61 | $104,733 |
| JardianceEmpagliflozin | 77 | $74,884 |
| MounjaroTirzepatide | 36 | $54,831 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 17 | $31,515 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $24,677 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $21,739 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $16,475 |
| FarxigaDapagliflozin Propanediol | 11 | $16,285 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $15,492 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $13,724 |
| LantusInsulin Glargine,hum.Rec.Anlog | 17 | $5,234 |
| Humalog Kwikpen U-100Insulin Lispro | 18 | $4,284 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 12 | $3,775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $384 | $172,88995 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $589 | $159,56497 claims |
| Radius Health, Inc.Tymlos | $68 | $111,32536 claims |
| Boehringer IngelheimJardiance | $185 | $74,88477 claims |
| AstraZenecaFarxiga | $216 | $16,28511 claims |
| Sanofi-aventis U.S. LLCLantus | $207 | $5,23417 claims |
| AbbVieSynthroid | $73 | $1,84019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,756 physician assistant providers in Oregon.
Other physician assistant in Portland
- Sean BrownPortland$43K
- Meegan MangumPortland$25K
- Scott FrazeePortland$24K
- Lucy NusralaPortland$9K
- Thomas SextonPortland$9K
- Madelyn DoPortland$8K
- Kevin BrandtPortland$8K
- Virginia WhitneyPortland$8K
- Mary BurnellPortland$7K
- William SimpsonPortland$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.